WILMINGTON, DE — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) said its subsidiary, HOPE Therapeutics, has begun treating patients using an artificial intelligence-guided transcranial magnetic stimulation system, a move the company says supports its broader strategy to combine precision neuromodulation with drug therapies for depression and other neuropsychiatric disorders.
The first treatments using Zeta Surgical’s FDA-cleared Zeta TMS Navigation System are underway at HOPE clinics in West Palm Beach and Sarasota, Florida, marking the transition from research deployment to routine patient care.
The system uses artificial intelligence and computer vision to align a patient’s MRI or CT images with facial anatomy and continuously track the position of the TMS coil relative to targeted brain regions with sub-millimetric accuracy.
NRx said the deployment advances its interventional psychiatry platform and aligns with plans to study its investigational therapy NRX-101 in combination with robotic-enabled TMS in patients with depression and suicidality.
“Treating our first patients with the Zeta TMS Navigation System moves the integrated treatment model we are building at HOPE from concept to clinical reality,” said Jonathan Javitt, chairman and chief executive officer of NRx Pharmaceuticals and HOPE Therapeutics.
TMS is a non-invasive treatment used primarily for patients with treatment-resistant depression, a condition affecting roughly one-third of people diagnosed with major depressive disorder. The therapy is also used to treat other neuropsychiatric disorders, including obsessive-compulsive disorder.
Because TMS works by stimulating specific brain regions and neural circuits, accurate targeting is considered an important factor in treatment delivery. NRx said the Zeta system is designed to improve the precision and repeatability of those treatments.
The deployment also supports the company’s planned SPARC-TMS trial, which is expected to evaluate NRX-101, an oral combination of D-cycloserine and lurasidone, alongside robotic-enabled TMS. The trial is planned across a U.S. academic teaching hospital, three HOPE clinics and two military treatment facilities.
HOPE’s broader treatment platform includes ketamine and Spravato administration, TMS, hyperbaric oxygen therapy and other neuroplasticity-focused therapies offered through its clinic network.
The announcement comes as healthcare providers increasingly seek to integrate artificial intelligence and precision technologies into psychiatric care, particularly for patients with treatment-resistant conditions and limited therapeutic options.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.